MAGE-c2-specific TCRs combined with epigenetic drug-enhanced antigenicity yield robust and tumor-selective T cell responses

2016-09-15

Journal of Immunology , Volume 197 - Issue 6 p. 2541- 2552

Additional Metadata
Persistent URL	doi.org/10.4049/jimmunol.1502024, hdl.handle.net/1765/93481
Journal	Journal of Immunology
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Kunert, A., van Brakel, M., van Steenbergen-Langeveld, S., Da Silva, M. (Marvin), Coulie, P., Lamers, C., … Debets, R. (2016). MAGE-c2-specific TCRs combined with epigenetic drug-enhanced antigenicity yield robust and tumor-selective T cell responses. Journal of Immunology, 197(6), 2541–2552. doi:10.4049/jimmunol.1502024

Publication